DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sotret (Isotretinoin) - Summary



Sotret must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin capsules in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected.

Birth defects which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported.

Documented external abnormalities include: skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain of the abnormalities previously noted.

If pregnancy does occur during treatment of a female patient who is taking isotretinoin capsules, isotretinoin capsules must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Special Prescribing Requirements

Because of isotretinoin’s teratogenicity and to minimize fetal exposure, Sotret is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This program is called iPLEDGE™. Sotret must only be prescribed by prescribers who are registered and activated with the iPLEDGE program. Sotret capsules must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are registered and meet all the requirements of iPLEDGE (see PRECAUTIONS).

Table 1 Monthly Required iPLEDGE Interactions

Female Patients of Childbearing Potential Male Patients, And Female Patients Not of Childbearing Potential
Confirms patient counselingXX
Enters the 2 contraception methods chosen by the patientX
Enters pregnancy test resultsX
Answers educational questions before every prescriptionX
Enters 2 forms of contraceptionX
Calls system to get an authorizationXX




Isotretinoin, a retinoid, is available as Sotret in 10 mg, 20 mg, 30 mg, and 40 mg soft gelatin capsules for oral administration. Each capsule contains butylated hydroxyanisole, edetate disodium, hydrogenated soybean oil, hydrogenated vegetable oil, iron oxide black, soybean oil and white wax. Gelatin capsules contain glycerin and parabens (methyl and propyl), with the following dye systems: 10 mg - iron oxide (red) and titanium dioxide; 20 mg - FD&C Red No. 3, FD&C Blue No. 1, and titanium dioxide; 30 mg - FD&C Yellow No. 6, and titanium dioxide; 40 mg - FD&C Yellow No. 6, D&C Yellow No. 10, and titanium dioxide.

Sotret is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition,2 means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Sotret should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Sotret is indicated only for those female patients who are not pregnant, because Sotret can cause severe birth defects (see Boxed CONTRAINDICATIONS AND WARNINGS).

A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off isotretinoin capsules. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see WARNINGS: Skeletal: Bone Mineral Density, Hyperostosis, and Premature Epiphyseal Closure).

See all Sotret indications & dosage >>


Published Studies Related to Sotret (Isotretinoin)

A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris. [2011.06]
In this randomized clinical trial, 39 patients with psoriasis vulgaris were randomized in two groups. Intervention group received narrow band ultraviolet B (NBUVB)+isotretinoin (0.5 mg/kg/day), control group received NBUVB+placebo.

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. [2010.11]
External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone...

Mortality in the randomized, controlled lung intergroup trial of isotretinoin. [2010.06]
In 2001, we reported that mortality may have been higher with isotretinoin (30 mg/d for 3 years) than with placebo in the subgroup of current smokers among the 1,166 patients with definitively resected early-stage non-small cell lung cancer who participated in the randomized, controlled Lung Intergroup Trial...

A randomized and controlled trial about the use of oral isotretinoin for photoaging. [2010.02]
Topical retinoids are used to treat photoaging; oral isotretinoin is gold standard for acne; "off label" indications, including photoaging, have been reported with insufficient evidence of efficacy. This is a randomized controlled phase II trial with clinical and histological assessment to evaluate efficacy and safety of oral isotretinoin for photoaging...

Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. [2010]
Using data from a randomized, double blind, study of the efficacy of retinol or isotretinoin vs. placebo on recurrence of nonmelanoma skin cancer in high-risk subjects, a reanalysis of the original intent to treat analysis was performed in a dose-response format...

more studies >>

Clinical Trials Related to Sotret (Isotretinoin)

Aflac ST1001 Prolonged Isotretinoin [Recruiting]
Neuroblastoma is a cancer of the nervous system and accounts for 15% of cancer related deaths in children. With the advancement of treatment therapies, the long term survival rate has progressed to approximately 50%. The therapy used for treatment, however, is very toxic and associated with serious long-term side effects. Treatment for neuroblastoma typically includes chemotherapy, surgery, stem cell transplantation, radiation therapy, and immunotherapy. At the end of this treatment, children with neuroblastoma commonly take the drug isotretinoin for 6 months. Isotretinoin maintains the response to previous treatments and helps turn the remaining cancer cells into normal nerve cells.

Most patients often respond to this treatment at first but are at a high-risk for the cancer coming back. The majority of the children who relapse after treatment or develop recurrent disease do so in the first two years following the completion of therapy and there are no current treatments to cure those who relapse. This study will explore whether or not extending the therapy with isotretinoin from 6 months to 24 months will help prevent the cancer from coming back without causing severe side effects.

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma [Recruiting]
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may help cells that are involved in the body's immune response to work better. Giving erlotinib hydrochloride together with isotretinoin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given with isotretinoin in treating patients with recurrent malignant glioma.

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma [Recruiting]
This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may help vorinostat work better by making tumor cells more sensitive to the drug. Giving vorinostat together with isotretinoin may be an effective treatment for neuroblastoma

A Feasibility Study of SAHA Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System [Recruiting]
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. A peripheral blood stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. This clinical trial is studying the side effects of giving vorinostat and isotretinoin together with combination chemotherapy and to see how well it works in treating young patients who have undergone surgery for embryonal tumors of the central nervous system

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) [Recruiting]

Phase I

1. To determine the maximum tolerated dose (MTD) of vorinostat/isotretinoin (cRA), temozolomide (TMZ)/cRA and vorinostat/cRA/TMZ combinations in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.

Phase II

Primary objective:

1. To determine the efficacy of vorinostat/cRA versus TMZ/cRA versus vorinostat/cRA/TMZ in patients with recurrent GBM as determined by Progression Free Survival (PFS) using an adaptive randomization phase II trial design.

Secondary objectives:

2. To determine the radiological response, progression free survival at 6 months, overall survival and unexpected toxicity in the three treatment arms.

3. To obtain exploratory data regarding histone 3 and 4 acetylation and p21 levels in tumor tissue and peripheral monocytes in a subset of surgical patients and in non-surgical patients with available tissue from previous surgical procedures.

4. To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) self-reporting tool.

more trials >>

Reports of Suspected Sotret (Isotretinoin) Side Effects

Inflammatory Bowel Disease (91)Colitis Ulcerative (47)Depression (33)Irritable Bowel Syndrome (29)Crohn's Disease (28)Anxiety (23)Blood Cholesterol Increased (19)Blood Triglycerides Increased (18)LIP DRY (13)DRY Skin (13)more >>


Based on a total of 10 ratings/reviews, Sotret has an overall score of 8. The effectiveness score is 9.40 and the side effect score is 5.80. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.

Sotret review by 18 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Moderate Side Effects
Treatment Info
Condition / reason:   Acne
Dosage & duration:   40mg taken twice a day for the period of 6 months
Other conditions:   None
Other drugs taken:   None
Reported Results
Benefits:   Smooth, clear skin. The Roaccutane not only got rid of my acne but also rejuvenated my skin. Pores were finer, blackheads were gone.
Side effects:   Dry lips, red skin for the first month or so.
Comments:   Treatment consisted of orally taking two tablets a day. I was prescribed Cetaphil lotion and lip balm to keep side effects at bay. Roaccutane was an excellent treatment. Before going on it I spent hundreds of dollars on other anti-acne treatments such as Clearasil etc and had no joy. Don't waste your money on other treatments just see your GP and ask for Roaccutane if you have an ongoing acne problem.


Sotret review by 26 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Moderate Side Effects
Treatment Info
Condition / reason:   mild but resistant acne
Dosage & duration:   30mg/day taken 2 doses for the period of 4 months - repeated after 1 year for 3m
Other conditions:   rosacea (mild)
Other drugs taken:   contraceptive pill
Reported Results
Benefits:   Treatment was very effective, effects started to be noticeable after 3 weeks. After 3 months skin had cleared and as additional benefits, hair and skin were much less oily (no longer needed to wash hair daily as it was not so oily any more. Pores shrunk and much less visible.
Side effects:   Side effects started about 3 days after starting treatment. Initially lips became very dry and had to use lip salve continuosly. Then I started getting nosebleeds as the skin inside my nose became very dry and fragile. Skin became very dry and sensitive during treatment and eyes very sensitive to light. I had to have regular blood tests to check my lipid profile but it was not affected by the treatment. During the second course of treatment I also got very mild depression symptoms so I stopped the treatment.
Comments:   I suffered with mild acne and many whiteheads that were resistant to all other topical and antibiotic treatment. My dermatologist was reluctant to prescribe Accutane as I had a mild acne but eventually let me try a course at the lowest dose (0.5/mg/kg). I had 2 courses of treatment with Accutane. The first time it was highly effective (side effects were tolerable and worth it as I got great results) so I stopped after 4 months. after about a year the acne returned (much less than previously) so I took another course and after that it was definitely gone. There are side effects but if you can tolerate them, it is a very effective treatment. I had to do a pregnancy test prior to starting each course and full blood test and had to take oral contraceptives throughout the treatment as there is a risk of birth defects. I also had to see dermatologist every 2 weeks initially then monthly and have my blood tests repeated. Tretment was very expensive (including cost of drugs, blood tests, consultation fees) but worth it.


Sotret review by 24 year old male patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Severe Side Effects
Treatment Info
Condition / reason:   Acne
Dosage & duration:   80mg per day taken once daily for the period of 20 weeks
Other conditions:   None
Other drugs taken:   None
Reported Results
Benefits:   Cleared active acne very effectively.
Side effects:   Dry, cracked lips. Dark eye are due to thinning of skin. Extreme photosensitivity. Very dry, coarse skin.
Comments:   Four 20 mg capsules taken once daily. Also had to double reccommended daily water intake. Moisturised skin and lips when absolutell necessary although this was not advised by dermatologist due to clogging of pores.

See all Sotret reviews / ratings >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015